11 completed, 9 unknown, 6 recruiting, 3 active not recruiting. 35 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 35 | Completed 11, Unknown 9, Recruiting 6, Active not recruiting 3, Not yet recruiting 3, Terminated 3 |
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
Follow Epithelial Ovarian Cancer: new trials by email Literature Review of Epithelial Ovarian Cancer trials Research Report on Epithelial Ovarian Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers BG-C9074, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | BeOne Medicines | 600 | 2026-10-01 | 2026-09-10 |
| Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer Torvutatug samrotecan, Bevacizumab - Epithelial Ovarian Cancer | Phase 3 | Recruiting | AstraZeneca | 950 | 2026-09-16 | 2026-11-06 |
| A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer BL-M07D1, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 404 | 2026-07-01 | 2026-06-29 |
| AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel - Epithelial Ovarian Cancer | Phase 3 | Recruiting | AstraZeneca | 1100 | 2025-12-29 | 2026-07-21 |
| A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 450 | 2025-08-04 | 2026-07-07 |
| Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin - Epithelial Ovarian Cancer, Ovarian Cancer | Phase 3 | Recruiting | Imunon | 500 | 2025-07-09 | 2026-10-30 |
| Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer Fluzoparib, Apatinib Mesylate - Epithelial Ovarian Cancer, Efficacy | Phase 3 | Unknown | Anhui Provincial Hospital | 51 | 2024-10-01 | 2024-08-06 |
| Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC Neoantigen polypeptide vaccine - Epithelial Ovarian Cancer | Phase 2 / Phase 3 | Recruiting | Second Affiliated Hospital of Wenzhou Medical University | 10 | 2024-01-01 | 2024-04-02 |
| REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 2 / Phase 3 | Terminated | Sutro Biopharma, Inc. | 600 | 2023-07-12 | 2025-09-23 |
| A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer Mirvetuximab Soravtansine - Epithelial Ovarian Cancer, Peritoneal Cancer | Phase 3 | Unknown | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 35 | 2022-08-18 | 2022-11-21 |
| CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER) HIPEC - Epithelial Ovarian Cancer, Platinum Resistant | Phase 3 | Active not recruiting | National Cancer Center, Korea | 140 | 2022-04-07 | 2026-02-12 |
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib Rucaparib - Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer | Phase 3 | Completed | pharmaand GmbH | 34 | 2021-03-22 | 2024-05-07 |
| Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) Primary debulking surgery, Neoadjuvant chemotherapy, PARPi - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 410 | 2021-01-01 | 2020-08-27 |
| A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation CRS+HIPEC, CRS alone - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 3 | Unknown | CAI Hongbing | 280 | 2020-08-01 | 2020-09-09 |
| A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Mirvetuximab Soravtansine - Epithelial Ovarian Cancer, Peritoneal Cancer | Phase 3 | Completed | ImmunoGen, Inc. | 106 | 2020-07-23 | 2024-08-07 |
| Efficacy of Letrozole in Recurrent Ovarian Cancer Letrozole 2.5mg, Standard single agent chemotherapy - Epithelial Ovarian Cancer | Phase 3 | Terminated | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 86 | 2020-06-22 | 2025-03-07 |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression Mirvetuximab Soravtansine, Paclitaxel, Topotecan - Epithelial Ovarian Cancer, Peritoneal Cancer | Phase 3 | Completed | AbbVie | 453 | 2019-12-31 | 2025-08-27 |
| Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery Hyperthermic Intraperitoneal Chemotherapy, cytoreductive surgery, adjuvant chemotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Unknown | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 310 | 2019-10-15 | 2019-11-06 |
| Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer Long-acting granulocyte colony stimulating factor, Short-acting granulocyte colony stimulating factor - Chemotherapy-induced Neutropenia, Febrile Neutropenia, Drug-Induced | Phase 3 | Unknown | Lei Li | 200 | 2019-10-01 | 2019-10-08 |
| Long-acting G-CSF for Febrile Neutropenia long-acting granulocyte colony stimulating factor, Short-term granulocyte colony stimulating factor - Epithelial Ovarian Cancer, Colony Stimulating Factors | Phase 3 | Unknown | Lei Li | 556 | 2018-11-10 | 2018-11-14 |
Showing 20 of 35. Sign in to see all of them.
Carcinoma, Ovarian Epithelial (35) · Fallopian Tube Neoplasms (21) · Ovarian Neoplasms (14) · Neoplasms (2) · Carcinoma (1) · Chemotherapy-Induced Febrile Neutropenia (1) · Febrile Neutropenia (1) · Genital Neoplasms, Male (1) · Malnutrition (1) · Pathologic Complete Response (1) · Peritoneal Neoplasms (1) · Prostatic Neoplasms (1) · Recurrence (1)
Adnexal Diseases (35) · Endocrine Gland Neoplasms (35) · Endocrine System Diseases (35) · Female Urogenital Diseases (35) · Female Urogenital Diseases and Pregnancy Complications (35) · Genital Diseases (35) · Genital Diseases, Female (35) · Genital Neoplasms, Female (35) · Gonadal Disorders (35) · Neoplasms by Histologic Type (35) · Neoplasms by Site (35) · Neoplasms, Glandular and Epithelial (35) · Ovarian Diseases (35) · Urogenital Diseases (35) · Urogenital Neoplasms (35)
Paclitaxel (10) · Topotecan (7) · liposomal doxorubicin (7) · Hyperthermic Intraperitoneal Chemotherapy (6) · mirvetuximab soravtansine (5) · Carboplatin (3) · Chemotherapy, Adjuvant (3) · rucaparib (3) · Bevacizumab (2) · CP protocol (2) · Gemcitabine (2) · Neoadjuvant Therapy (2) · olaparib (2) · Cisplatin (1) · Cytoreduction Surgical Procedures (1)
AstraZeneca (3) · pharmaand GmbH (3) · ImmunoGen, Inc. (2) · Japanese Gynecologic Oncology Group (2) · Lei Li (2) · National Cancer Center, Korea (2) · Shanghai Gynecologic Oncology Group (2) · Sichuan Baili Pharmaceutical Co., Ltd. (2) · AbbVie (1) · Affiliated Cancer Hospital & Institute of Guangzhou Medical University (1) · Anhui Provincial Hospital (1) · BeOne Medicines (1) · CAI Hongbing (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Gynecologic Oncology Trial & Investigation Consortium (1)
China (16) · Italy (10) · South Korea (10) · United States (10) · Canada (9) · Israel (9) · Spain (9) · United Kingdom (8) · Australia (7) · Belgium (7) · Czechia (7) · Poland (7) · Germany (6) · Japan (6) · Russia (6)
Lei Li, M.D. (2) · Shuzhong Cui, M.D (2) · Zhongqiu Lin, M.D (2) · Andreas Obermair, MD FRANZCOG CGO (1) · Claudia Marchetti (1) · Eric Pujade-Lauraine, MD, PhD (1) · Ignace Vergote, Prof. (1) · Keiichi Fujiwara, MD, PhD (1) · Makoto Yasuda, M.D. (1) · Michael Method, MD, MPH, MBA (1) · Pedro Villarejo Campos, MD, PhD (1) · Ping Duan, Master (1)
PMID 19169758, PMID 19767092, PMID 23948349, PMID 24356636, PMID 25827292, PMID 31467066, PMID 31826802, PMID 32808504, PMID 33667670, PMID 34593565, PMID 35262624, PMID 35298906, PMID 35658487, PMID 35712968, PMID 36608383, PMID 36716407, PMID 37212825, PMID 37407274, PMID 37797734, PMID 38055253, PMID 38858103, PMID 39914419, PMID 39955184, PMID 40179908, PMID 41115469
2016 (1), 2017 (1), 2019 (1)